upgrad mdso op
upgrad mdso outperform upgrad mdso share outperform
sector perform compani maintain enviabl posit drug research space
key tenet upgrad increas confid compani revenu earn visibl
help strong public privat fund rais environ biopharma compani stabl
 spend environ establish pharma biotech research sponsor palat
valuat rel histori market given strength tailwind search less
amazon-rel headlin risk coverag group see drug research space like continu
attract capit healthcar servic investor look growth avoid compet
capit rais environ show unpreced strength pwc recent releas vc fund
report note biotech vc fund grew y/i across deal
increas deal second consecut quarter record-high fund
addit privat capit rais biotech ipo set continu rebound low-wat
mark biotech ipo rais billion doubl billion
figur like exceed biotech compani alreadi rais billion less
seven month anoth million file backlog yet price
public market strength biotech fund posit indic mdso work
extens biotech compani drug develop process
intra-sector shift healthcar servic investor besieg numer themat
headwind face drug suppli chain amazon drug price regulatori chang vertic integr
etc lack market momentum hcit investor look place put money
work believ pharma servic compani well posit themat capit inflow given
palat valuat long-term revenu visibl lack either regulatori competit
valuat palat risk manag upgrad mdso outperform sector
perform revis price target mdso share repres ev/sal multipl
appli sale estim price target share
repres price-to-earnings multipl appli ep estim maintain outperform
rate rais price target roll forward valuat
ep one risk thesi larg cap pharma acceler long fear
neg outsourc servic provid addit slow-down industri fund could
threaten capit biotech compani develop new drug erod potenti market
opportun mdso mitig last risk howev year revenu
visibl afford current flush vc fund landscap
exhibit summari rate price target chang exhibit revis
estim mdso model page
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
drug research servic stoppin us upgrad mdso op
intra-sector rotat upgrad mdso outperform
upgrad mdso share outperform sector perform view
compani enviabl posit respect space market outsourc
 servic technolog global leader outsourc preclin
servic medidata clinic research industri lead edc technolog vendor
expect compani capit continu sector-wid theme includ favor
fund backdrop privat public market biotech compani stabl larg cap
pharma biotech spend expect focu increas use technolog
outsourc servic space
respect charl river expect see continu growth discoveri segment
research model busi sourc leverag stabil recent met
charl river execut discuss growth discoveri segment manag
character end market still earli outsourc process pharma
still see discoveri part core compet execut estim
discoveri servic market billion dollar end market penetr
put discoveri much farther curv compar safeti assess
manag estim billion market outsourc rate insid
discoveri compani continu see strong demand outsourc assay work high
throughput screen combinatori chemistri crystallographi servic
also met medidata execut recent dia confer boston dia
floor medidata booth teem custom prospect receiv demonstr
recent shyft acquisit sizabl presenc medidata booth compani
tout real-world evid capabl edc matur compani expect risk-
base monitor trial assur genom tool synthet control arm start
repres larger portion year-over-year growth compani hope
would crack list conced product behind medidata
continu develop par offer answer
compani continu success face mount competit like
veeva medidata point long record accomplish client success strateg
vision custom buy strong foundat technolog platform
believ compani enviabl footprint commerci trial sponsor
strong demand increasingli sophist solut trial process drive
cross-sal opportun continu revenu growth medidata
strong fundament asid believ stock could continu see benefit
intra-sector rotat investor look de-risk portfolio threat amazon-rel
news amazon entri variou end market mega-them last sever
year earli began impact drug suppli chain name cover look
build amazon-resist stock recommend early- late-stag outsourc
servic appear one safer haven investor
mdso recent seen good run ytd mdso
believ strong underli fundament continu power above-averag
oper perform lead continu share price out-performance henc upgrad
share compani outperform sector perform
drug research servic stoppin us upgrad mdso op
pricewaterhousecoop recent releas vc fund report note
biotech vc fund grew y/i q/q across deal increas
deal second consecut quarter record-high
fund like driven financ round aim advanc novel therapi
clinic trial optim tax reform driven repatri cash lead increas
biopharma believ reflect grow investor confid higher valuat
support earli clinic trial result strength biotech fund posit indic
mdso work extens biotech compani drug
develop process compani gener revenu
development-stag biopharma compani spend cycl typic last
month trial process start data give us high level confid
strength end market least next two year revenu gener though
note book cancel lumpi
exhibit vc fund higher
drug research servic stoppin us upgrad mdso op
exhibit vc fund almost rate
fundrais sinc
addit privat biopharma fundrais public market capit rais biotech
compani also continu torrid pace sinc low biotech ipo rais billion
doubl billion figur like exceed
biotech compani alreadi rais billion less seven month
anoth million file backlog yet price public market
mani development-stag compani use ipo proce fund clinic
develop program becom book backlog revenu compani like
iqvia medidata henc view extrem strong public privat capit rais
environ activ lead indic futur revenu growth clinic
research compani cover
drug research servic stoppin us upgrad mdso op
exhibit biotech ipo teeter reacceler
ipo pick biotech
compani
money drug
provid bigger
exhibit proce biotech ipo almost reach total
establish sponsor spend steadi goe
outsid early- development-stag biotech outsourc research budget big pharma
big biotech appear show steadi modest growth look consensu estim
 spend largest commerci drug develop see expect total
spend growth establish trial sponsor
spend usual repres revenu medidata biotech
repres balanc expect establish player includ charl river
medidata iqvia continu take share outsourc servic space sponsor
repeatedli say look larger better partner work provid
comprehens suit solut either servic technolog need
drug research servic stoppin us upgrad mdso op
exhibit spend biotech expect outpac pharma
compani
light infrastructur
expect grow
quickli big
develop pharma
 chang chang chang chang chang year pharma drug research servic stoppin us upgrad mdso op
exhibit consensu estim declin increas pharma
expect
declin like part due
slow-down ipo
earli
expect
estim trend upward
ipo continu
prolifer addit
view growth
suggest investor
shrug fear
lead cut
drug research servic stoppin us upgrad mdso op
project ep y/i vs street guidanc
revenu vs street guidanc
make ep estim chang time roll
forward valuat ep given half
strong fundrais data increas confid estim
exhibit estim vs street
ep estim
ahead consensu
 estim changerevenueresearch model servic safeti assess oper oper incom net ep drug research servic stoppin us upgrad mdso op
rais ep vs street revenu
vs street guidanc increas ep
project result improv oper margin vs prior project
compani matur manag continu drive effici throughout
busi expect oper effici continu result
oper margin vs prior project ep vs prior forecast
exhibit estim vs street mdso
estim mdso
modestli ahead
 estim oper incom oper incom non-gaap net non-gaap ep drug research servic stoppin us upgrad mdso op
exhibit mdso edc market leader among pharma
rais rate price target mdso
exhibit summari rate price target chang
rais rate mdso outperform sector perform revis price
target mdso repres ev/sal multipl appli sale estim
multipl base averag top half saa peer group
valuat believ justifi given favor industri dynam
compani compar growth rate group also medidata approach billion-
dollar revenu target believ share abl sustain premium
market tend appli saa compani billion recur revenu
compani revenu edc platformjohnson medidataroch medidatapf oraclenovarti medidatamerck medidataglaxosmithklin oracleabbvi medidatagilead scienc medidata lilli oracleamgen medidataastrazeneca medidatateva pharmaceut industri medidataboehring medidatabristol-my squibb medidatamerck oraclenovo nordisk oracletakeda pharmaceut co medidataallergan oracleshir oraclecelgen medidataastella pharma medidatamylan oracleotsuka hold co medidatabiogen medidatadaiichi sankyo compani medidatabausch health n/apric rate chang summarymdsoiqvoldnewoldnewoldnewratingsector performoutperformsector performoutperformoutperformoutperformpric drug research servic stoppin us upgrad mdso op
price target repres price-to-earnings multipl appli ep estim
previous appli price-to-earnings multipl ep estim
premium histor trade multipl reflect better busi mix greater
outsourc early-stag stabil rm segment higher multipl
broader market note howev target multipl essenti place
valuat target essenti line premium market share
histor trade
rais price target roll forward valuat ep
one risk thesi larg cap pharma turn develop
drug in-hous compani unlik biotech compani often capac
develop infrastructur make develop drug minim usag cro feasibl
addit slow-down vc fund could threaten capit biotech compani
develop new drug erod potenti market opportun mdso
mitig last risk howev year revenu visibl afford
valuat target could appear optimist believ warrant given
strength research end market impact amazon effect part
coverag univers amazon recent entranc pharmaci expect growth
medic product devic sever impact stock multipl part
coverag univers creat opportun compani attract capit investor
flee drug retail drug wholes medic product distribut share
exhibit mdso valuat ev/sal basi trade histor averag
valuat
mdso share like
sustain given
challeng
drug research servic stoppin us upgrad mdso op
exhibit valuat price-to-earnings basi trade histor averag
exhibit valuat price-to-earnings rel basi
drug research servic stoppin us upgrad mdso op
drug research servic stoppin us upgrad mdso op
exhibit street rate mdso share
upgrad less
consensu call
upgrad mdso
drug research servic stoppin us upgrad mdso op
price target mdso base ev/sal multipl appli
revenu estim million multipl base averag top half
saa peer group comp believ favor industri dynam compani
growth rate justifi multipl line highest-valu saa compani price
target support outperform rate believ share room run given
mdso enviabl posit market
risk rate price mdso
believ key risk rate price target subscript softwar growth
competit clinic trial softwar space valuat saa softwar peer group
expect mdso continu take market share edc ancillari solut space
stronger expect competit could limit market share gain result competit
displac also risk biopharma could drive market consolid
result limit clinic trial spend forecast solid long-term growth mdso
result could lumpi could risk forecast share price
out-performance next month
price target share base price-to-earnings ratio appli
estim premium histor price-to-earnings ratio share believ
justifi given mix shift attract busi greater outsourc
early-stag stabil rm segment higher multipl broader market
also reflect slightli higher histor premium multipl
believ justifi compani current growth prospect price target support
risk rate price
believ key risk rate price target book lumpi biopharma
 cancel book convers rate forecast continu demand
outsourc discoveri safeti assess slower expect spend growth
rate outsourc could result slower expect revenu growth forecast
steadi result us rm busi strong growth china wors expect
result either geographi could impact forecast
exhibit chang estim
price target base ep previous base
ep modest premium share trade
sinc ipo slightli histor premium multipl believ
premium histor multipl justifi given synergi im merger
compani uniqu posit posit view biopharma spend price
target support outperform rate
increas driven
updat share
chang adjust ebitda adjust ebitda drug research servic stoppin us upgrad mdso op
risk rate price
key risk rate price target biopharma spend trend execut
merger integr project sale cost synergi trend spend
drug research servic stoppin us upgrad mdso op
research model servic
discoveri safeti assess
revenu
revenu
amort intang
loss debt retir
depreci amort
incom continu oper net tax
incom loss discontinu busi net tax
net incom loss attribut common shareown
non- reconcili
net incom continu oper
amort relat acquisit
stock-bas compens relat inveresk acquisit
sever relat cost-sav action
impair charg
sale uk real estat
adjust conting consider relat acquisit
cost associ evalu acquisit
write-off defer financ cost relat debt extinguish
settlement life insur polici
tax expens repatri
tax benefit disposit phase clinic busi
drug research servic stoppin us upgrad mdso op
ttm app servic revenue
million
revenu
revenu
research develop
sale market
gener administr
oper expens
research develop
sale market
gener administr
total oper expens
revenu
revenu
revenu
revenu
revenu
interest rate debt
interest rate invest
non-cash interest expens convert senior note
revenu
tax impact stock-comp amort
net revenu
drug research servic stoppin us upgrad mdso op
revenu
revenu
sell gener administr
revenu
adjust estim conting consider
revenu
loss extinguish debt
incom incom tax equiti earn unconsolid affili
incom equiti earn unconsolid affili
equiti earn unconsolid affili
net incom attribut non-controlling interest
net incom attribut quintil transnat hold
sale busi
drug research servic stoppin us upgrad mdso op
